March 25, 2025 - 04:05

Shares in Asia exhibited a mixed performance on Tuesday, with notable declines in Chinese markets following a significant rally on Wall Street. The optimism in the U.S. was largely driven by expectations that the Trump administration might adopt a more focused strategy regarding the upcoming round of tariffs on imported goods, set to be announced next week.
In the wake of this news, U.S. futures experienced a slight dip, while oil prices remained relatively stable. Among the notable movements, Xiaomi, a prominent cell phone manufacturer, saw its shares traded in Hong Kong fall by 5.4%. Similarly, the delivery app firm Meituan faced a decline of 4.2%.
These fluctuations reflect the ongoing uncertainty in global markets as investors remain cautious ahead of new trade policies and their potential impact on the economic landscape. The mixed results highlight the delicate balance between optimism and caution as market participants navigate the evolving situation.
November 12, 2025 - 19:08
Aeluma Reports Strong Financial Performance for First Quarter of Fiscal 2026Aeluma, Inc., a leading semiconductor company known for its innovative high-performance technologies, has announced its financial results for the first quarter of fiscal 2026, which concluded on...
November 12, 2025 - 07:43
Celebrating Excellence: Winners of the 2025 US Women in Finance AwardsThe 2025 US Women in Finance Awards have recognized outstanding contributions from women leaders in the financial sector. Among the notable winners, Mitali Sohoni from Citi has been honored for her...
November 11, 2025 - 19:48
Key Metrics to Monitor in Disney's Upcoming Earnings ReportDisney is set to release its earnings report on Thursday, marking a significant moment as it will disclose subscriber numbers for the last time. Analysts are keenly focused on three critical...
November 11, 2025 - 01:05
ProKidney Announces Q3 2025 Financial Outcomes and Key DevelopmentsProKidney has released its financial results for the third quarter of 2025, highlighting significant progress in its clinical studies and regulatory endeavors. The company recently showcased full...